Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.
- 1 February 1991
- journal article
- Vol. 23, 928-30
Abstract
FK 506 therapy with low doses of steroids was adequate to control rejection in most liver recipients. Rejection episodes were readily reversed with single IV doses of methylprednisone or hydrocortisone. Short courses of OKT3 (3 to 5 days 5-10 mL) controlled severe rejections. The rate of retransplantation directly due to rejection was low (1.6%). There was a limited need for steroids either early or out to 6 to 12 months.This publication has 9 references indexed in Scilit:
- Liver, Kidney, and Thoracic Organ Transplantation Under FK 506Annals of Surgery, 1990
- FK 506 dosage in human organ transplantation.1990
- Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.1990
- FK 506 FOR LIVER, KIDNEY, AND PANCREAS TRANSPLANTATIONThe Lancet, 1989
- Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction.1988
- Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine.1987
- Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.1987
- IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION1987
- FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.The Journal of Antibiotics, 1987